Research ExplorerPublicationsProliferation signal inhibitors in transplantation: question...

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.

Standard

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. / Chapman, J R; Valantine, H; Albanell, J; Arns, W A; Campistol, J M; Eisen, H; Frigerio, M; Lehmkuhl, H; Marcen, R; Morris, R; Nashan, Björn; Pascual, J; Pohanka, E; Segovia, J; Zuckermann, A.

In: TRANSPL P, Vol. 39, No. 10, 10, 2007, p. 2937-2950.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chapman, JR, Valantine, H, Albanell, J, Arns, WA, Campistol, JM, Eisen, H, Frigerio, M, Lehmkuhl, H, Marcen, R, Morris, R, Nashan, B, Pascual, J, Pohanka, E, Segovia, J & Zuckermann, A 2007, 'Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.', TRANSPL P, vol. 39, no. 10, 10, pp. 2937-2950. <http://www.ncbi.nlm.nih.gov/pubmed/18089298?dopt=Citation>

APA

Chapman, J. R., Valantine, H., Albanell, J., Arns, W. A., Campistol, J. M., Eisen, H., Frigerio, M., Lehmkuhl, H., Marcen, R., Morris, R., Nashan, B., Pascual, J., Pohanka, E., Segovia, J., & Zuckermann, A. (2007). Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. TRANSPL P, 39(10), 2937-2950. [10]. http://www.ncbi.nlm.nih.gov/pubmed/18089298?dopt=Citation

Vancouver

Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. TRANSPL P. 2007;39(10):2937-2950. 10.

Bibtex

@article{51c3ba3d12b54242b750dbedf5a49949,
title = "Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.",
abstract = "While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting {"}Proliferation signal inhibitors in transplantation: questions at the cutting edge,{"} this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.",
author = "Chapman, {J R} and H Valantine and J Albanell and Arns, {W A} and Campistol, {J M} and H Eisen and M Frigerio and H Lehmkuhl and R Marcen and R Morris and Bj{\"o}rn Nashan and J Pascual and E Pohanka and J Segovia and A Zuckermann",
year = "2007",
language = "Deutsch",
volume = "39",
pages = "2937--2950",
journal = "TRANSPL P",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

RIS

TY - JOUR

T1 - Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.

AU - Chapman, J R

AU - Valantine, H

AU - Albanell, J

AU - Arns, W A

AU - Campistol, J M

AU - Eisen, H

AU - Frigerio, M

AU - Lehmkuhl, H

AU - Marcen, R

AU - Morris, R

AU - Nashan, Björn

AU - Pascual, J

AU - Pohanka, E

AU - Segovia, J

AU - Zuckermann, A

PY - 2007

Y1 - 2007

N2 - While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting "Proliferation signal inhibitors in transplantation: questions at the cutting edge," this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.

AB - While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to improve long-term graft and patient survival rates following renal and heart transplantation. Among the recognized threats to long-term organ survival are chronic allograft dysfunction in the form of chronic allograft nephropathy and cardiac allograft vasculopathy, with long-term patient morbidity and mortality further compromised by higher than normal rates of posttransplant cardiovascular disease, infection, and malignancy. A growing body of evidence finds that the selection and dosing of immunosuppressive therapies can have great influence on long-term transplantation outcomes. Early evidence suggests that the proliferation signal inhibitors (PSIs), everolimus and sirolimus, might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the posttransplant patient. This review summarizes the emerging evidence for employing PSI-based immunosuppression to seek a balance between the goals of maximizing graft and patient survival, while minimizing the risks of adverse events and long-term complications. Based on the proceedings of an international gathering of nephrologists, cardiologists and surgeons at the inaugural PSI Forum meeting "Proliferation signal inhibitors in transplantation: questions at the cutting edge," this paper aims to provide both an evidence base and practical guidance for transplant physicians seeking to optimize their use of PSI treatment and highlights avenues of ongoing research into the clinical potential of this class of immunosuppressive therapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 39

SP - 2937

EP - 2950

JO - TRANSPL P

JF - TRANSPL P

SN - 0041-1345

IS - 10

M1 - 10

ER -